SecBot SecBot
PRESS-RELEASE ·Filed Mar 25, 2026

NKTX

Nkarta, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The extended cash runway into 2029 reduces near-term dilution risk, but investors should await clinical data in 2026 for material catalysts. The modest improvement in losses and expenses reflects cost discipline, but no efficacy data is yet available to support valuation.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.14
T+0 close · Mar 25, 2026 · via day close
Latest settled
+38.32%
T+60 · $2.96
Vs SPY
+24.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $2.14entry
  2. T+1 · 8mo ago −3.74%α −2.06% · $2.06
  3. T+5 · 8mo ago +8.41%α +6.78% · $2.32
  4. T+20 · 7mo ago +36.45%α +25.78% · $2.92
  5. T+60 · 5mo ago +38.32%α +24.37% · $2.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta reported financial results for Q4 and full year 2025, highlighting a cash balance of $295.1 million, which is expected to fund operations into 2029. The company advanced dose escalation in its NKX019 autoimmune therapy trial to 4 billion cells per dose and plans to present initial clinical data from Ntrust-1 and Ntrust-2 at a medical conference in 2026. Net loss was $104.1 million for the year, with R&D and G&A expenses declining slightly year-over-year.

Key Financial Metrics

EPS
$-1.41

Key Facts

  • Cash, cash equivalents, and investments totaled $295.1 million as of December 31, 2025, sufficient to fund operations into 2029.
  • Net loss was $104.1 million ($1.41 per share) for full year 2025, compared to $108.8 million ($1.60 per share) in 2024.
  • R&D expenses decreased to $90.4 million in 2025 from $96.7 million in 2024.
  • G&A expenses were flat at $31.6 million in 2025 vs. $31.5 million in 2024.
  • Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3, and 7 (total 12 billion cells per cycle).
  • Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026.

Financial Impact

Reduced annual net loss by $4.7 million and lowered R&D spend by $6.3 million YoY, while extending cash runway to 2029.

cash runwayR&D expensesnet losseps

Risk Factors

  • Clinical data from Ntrust-1 and Ntrust-2 is not expected until 2026, creating a long information vacuum.
  • As a clinical-stage biotech with no approved products, Nkarta remains highly dependent on trial outcomes and future funding.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262553

Track record

13 reports on NKTX

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026